Valuing Biotechnology Patents and Companies - IIPLA

Valuing Biotechnology Patents and Companies

Categories: IP COURSES
Wishlist Share
Share Course
Page Link
Share On Social Media

About Course

About the Course:

This session provides profound insights into deciphering the Food and Drug Administration’s biotech approval process. Robert LeBoyer — a leading biotech analyst with nearly 25 years of experience — discusses a variety of technology, clinical, regulatory, sales and marketing, and capital risks associated with evaluating biotech companies.

This course includes commentary on a variety of valuation issues that arise in connection with monoclonal antibodies, cell receptors, and intracellular signaling. A review of developments in cutting-edge technologies such as genomics, gene therapy, and RNAi is provided. Drivers of biotech products targeted towards cancer, infectious diseases, cardiovascular diseases, and orphan drugs is a particularly practical segment of this program.

This course illustrates financial analysis by providing a Product Pipeline Table, a Pipeline Valuation, a Biotech Company Revenue Projection, and a Comparable Company Table.

Course Length: Approx. 1.5 hours

Show More

Student Ratings & Reviews

No Review Yet
No Review Yet

Want to receive push notifications for all major on-site activities?

Make Payment to IIPLA

  • ✓ Valid number ✕ Invalid number
  • Minimum Payment is $100. Please note that if the amount entered is less than $100, the card will be charged for $100 for service management and processing.
  • Enter the details of the payment including invoice number or any other reason of payment.
  • $0.00
  • American Express
    Supported Credit Cards: American Express, Discover, MasterCard, Visa, JCB, Maestro

Buy WLF Dubai Delegate Ticket

Oops! We could not locate your form.